deltatrials
Active Not Recruiting PHASE1 Interventional 1-arm NCT01999491

A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma

Sponsor: M.D. Anderson Cancer Center

Interventions NC-4016
Updated 3 times since 2017 Last updated: Nov 26, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Cancers and Lymphoma and is currently ongoing. M.D. Anderson Cancer Center leads this study, which shows 3 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotRecruiting~Feb 2017 – ~May 2017 · 3 months · monthly snapshotRecruiting~May 2017 – present · 110 months · monthly snapshotActive Not Recruiting

Change History

3 versions recorded
  1. May 2017 — Present [monthly]

    Active Not Recruiting PHASE1

    Status: RecruitingActive Not Recruiting

  2. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE1

  3. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • NanoCarrier Co., Ltd.
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations